Heidelberg-based PromoCell reports that it has adopted custom GMP cell culture media services tailored for clinical applications and further manufacturing in the cell-based therapy industry. The company is offering excipient GMP-grade cell culture media manufacturing and guidance through the entire research-to-commercialization journey, according to Irma Börcsök, CEO.
“We noticed an increasing demand for advanced cell culture media in regenerative medicine and cell-based therapy, and we are thrilled to introduce our GMP cell culture medium service portfolio to the life science community at the ESGCT Congress,” said Börcsök.
“We’ve worked closely with our clients in clinical applications to ensure that both our custom GMP cell culture media services and our advanced cell culture media product portfolio ‘PromoExQ’ ensure the precision and compliance that modern translational research demands,” added Lucía Cespón, PhD, GMP business unit lead.
PromoCell will be exhibiting at Booth A35 at the 32nd ESGCT Congress in Seville, Spain, from October 7–10.
